UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2025
Commission File Number: 001-41661
JIN MEDICAL INTERNATIONAL LTD.
(Exact name of registrant as specified in its charter)
No. 33 Lingxiang Road, Wujin District
Changzhou City, Jiangsu Province
People’s Republic of China
(Address of Principal Executive Office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INCORPORATION BY REFERENCE
This report on Form 6-K (“Report”)
shall be deemed to be incorporated by reference into the registration statement on F-3 (File No. 333-288314) of Jin Medical International
Ltd., a Cayman Islands exempted company (the “Company”) filed with the U.S. Securities and Exchange Commission June 25, 2025),
(“Registration Statement”), and into each prospectus or prospectus supplement outstanding under the Registration Statement,
to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933,
as amended, or the Securities Exchange Act of 1934, as amended.
EXPLANATORY NOTE
The Company is furnishing this current report
on Form 6-K to provide its unaudited condensed consolidated financial statements for the six months ended March 31, 2025, attached as
Exhibit 99.1 to this report of foreign private issuer on Form 6-K,. and Management’s Discussion and Analysis of Financial Condition
and Results of Operations for the six months ended March 31, 2025 is attached as Exhibit 99.2 to this report of foreign private issuer
on Form 6-K
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Form 6-K Report and
the exhibits hereto contain certain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s
current expectations and projections about future events that the Company believes may affect its financial condition, results of operations,
business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,”
“assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,”
“projects,” “intends,” “plans,” “will,” “would,” “should,” “could,”
“may” or similar expressions.
Many of these statements
are based on our assumptions about factors that are beyond our ability to control or predict and are subject to significant risks and
uncertainties that are described more fully in “Item 3. Key Information-D. Risk Factors” on our annual report on Form 20-F
filed with the SEC on January 24, 2025. Any of these factors or a combination of these factors could materially affect our future results
of operations and the ultimate accuracy of the forward-looking statements. Fluctuations in our future financial results may negatively
impact the value of our Class A ordinary shares. In addition to these important factors, important factors that, in our view, could cause
actual results to differ materially from those discussed in the forward-looking statements include, among other things:
| ● | assumptions about our future financial and operating results,
including revenue, income, expenditures, cash balances, and other financial items; |
| ● | our ability to execute our growth, and expansion, including
our ability to meet our goals; |
| ● | current and future economic and political conditions; |
| ● | our capital requirements and our ability to raise any additional
financing which we may require; |
| ● | our ability to attract clients and further enhance our brand
recognition; |
| ● | our ability to hire and retain qualified management personnel
and key employees in order to enable us to develop our business; |
| ● | trends and competition in the education industry; |
| ● | other assumptions described in this Report underlying or relating
to any forward-looking statements. |
Should one or more of the
foregoing risks or uncertainties materialize, should any of our assumptions prove incorrect, or should we be unable to address any of
the foregoing factors, our actual results may vary in material and adverse respects from those projected in these forward-looking statements.
Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially
realized, that they will have the expected consequences to, or effects, on us. Given these uncertainties, prospective investors are cautioned
not to place undue reliance on such forward-looking statements.
The Company undertakes no
obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes
in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking
statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors
that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect
its future results in the Company’s annual report and other filings with the U.S. Securities and Exchange Commission. As a result,
you are cautioned not to rely on any forward-looking statements.
Financial Statements and Exhibits.
Exhibits:
| Exhibit No. |
|
Description |
| 99.1 |
|
Unaudited Condensed Consolidated Financial Statements as of March 31, 2024 and for the Six Months Ended March 31, 2025 and 2024. |
| 99.2 |
|
Operating and Financial Review and Prospects in Connection with the Unaudited Condensed Consolidated Financial Statements for the Six Months March 31, 2025 and 2024. |
| 101.INS |
|
Inline XBRL Instance Document |
| 101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB |
|
Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
SIGNATURES
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
| |
Jin Medical International Ltd. |
| |
|
|
| Date: August 20, 2025 |
By: |
/s/ Erqi Wang |
| |
|
Erqi Wang |
| |
|
Chief Executive Officer |
| |
By: |
/s/ Ziqiang Wang |
| |
|
Ziqiang Wang |
| |
|
Chief Financial Officer |
Jin Medical International Ltd.
